Squamous cell carcinoma - Жалпак Клеткалуу Карцинома
☆ AI Dermatology — Free Service
Германиянын 2022-жылдагы Stiftung Warentest жыйынтыгында ModelDerm менен керектөөчүлөрдүн канааттануусу телемедициналык акы төлөнүүчү консультацияларга караганда бир аз төмөн болгон.
Германиянын 2022-жылдагы Stiftung Warentest жыйынтыгында ModelDerm менен керектөөчүлөрдүн канааттануусу телемедициналык акы төлөнүүчү консультацияларга караганда бир аз төмөн болгон.
Squamous cell carcinoma well differentiated — Жанаша актиникалык кератоз байкалат.
relevance score : -100.0%
ReferencesSquamous cell carcinoma (SCC) Америка Кошмо Штаттарында, basal cell carcinomaдан кийин, экинчи орунда турат. Ал көбүнчө actinic keratosis деп аталган рак алдындагы жаралардан башталып, дененин башка бөлүктөрүнө жайылышы мүмкүн. Негизги себеби – убакыттын өтүшү менен топтолгон күндүн ультрафиолет (УК) нурларынын таасири. Дарылоо, адатта, хирургиялык алып салууну камтыйт, айрыкча, баш жана мойнундагы СКК үчүн. Нур терапиясы улгайган бейтаптар же хирургиялык кыла албагандар үчүн тандоо болуп саналат. Иммуносупрессия ССК коркунучун жогорулатат. Сейрек болсо да, SCC иммундук системасы начар бейтаптарда тез жайылышы мүмкүн. Үзгүлтүксүз текшерүү жана күндөн коргоо ССК бар адамдар үчүн маанилүү.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) адамдарда экинчи эң көп таралган рак болуп саналат жана анын учурлары артып жатат. CSCC адатта жакшы клиникалык жүрүм‑турум көрсөтөт, бирок жергиликтүү же дененин башка бөлүктөрүнө жайылышы мүмкүн. Окумуштуулар CSCC‑дин жаңы дарылоосуна алып баруучу конкреттүү жолдорду аныкташты. Иммунотерапиянын өнүгүшүнө мутациялардын көп болушу жана иммуносупрессияланган бейтаптарда коркунучтун жогорулашы түрткү болду. Бул себептен CSCC‑дин генетикалык тамырлары, конкреттүү молекулалар жана иммундук система багытталган акыркы дарылоолор каралат.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Диагностика жана дарылоо
#Dermoscopy
#Skin biopsy